Kenvue Reports Second Quarter 2026 Results
Kenvue reported second-quarter net sales of $3.96 billion, up 3.0% year-over-year with organic growth of 1.6%. Diluted EPS rose 9% to $0.24, while adjusted EPS increased 7% to $0.31, marking the third consecutive quarter of growth across all segments and regions. The company achieved a significant regulatory milestone with FDA approval for Tylenol with Naproxen, the first OTC fixed-dose combination of acetaminophen and naproxen sodium. This product is supported by eight clinical studies and benefits from a three-year exclusivity period, with availability expected soon at major retailers.
Key figures
- Eps
- 0.24
- Revenue
- 3955000000
- Drug Name
- Tylenol with Naproxen
- Revenue Yoy
- 3.0%
- Fcf
- 1000000000
- Adjusted eps
- 0.31
- Gross margin
- 58.2%
- Operating margin
- 17.7%
- Organic sales growth
- 1.6%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.